In the past week, MURA stock has gone down by -61.46%, with a monthly decline of -57.77% and a quarterly plunge of -48.09%. The volatility ratio for the week is 7.86%, and the volatility levels for the last 30 days are 6.66% for Mural Oncology plc The simple moving average for the past 20 days is -55.33% for MURA’s stock, with a -53.42% simple moving average for the past 200 days.
Is It Worth Investing in Mural Oncology plc (NASDAQ: MURA) Right Now?
MURA has 36-month beta value of 3.04. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MURA is 15.34M, and currently, short sellers hold a 2.32% ratio of that float. The average trading volume of MURA on March 25, 2025 was 156.32K shares.
MURA) stock’s latest price update
Mural Oncology plc (NASDAQ: MURA)’s stock price has decreased by -57.44 compared to its previous closing price of 3.83. However, the company has seen a -61.46% decrease in its stock price over the last five trading sessions. benzinga.com reported 2025-03-25 that On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
Analysts’ Opinion of MURA
Many brokerage firms have already submitted their reports for MURA stocks, with Rodman & Renshaw repeating the rating for MURA by listing it as a “Buy.” The predicted price for MURA in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on June 28, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see MURA reach a price target of $13. The rating they have provided for MURA stocks is “Overweight” according to the report published on April 04th, 2024.
MURA Trading at -57.71% from the 50-Day Moving Average
After a stumble in the market that brought MURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.16% of loss for the given period.
Volatility was left at 6.66%, however, over the last 30 days, the volatility rate increased by 7.86%, as shares sank -55.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.92% lower at present.
During the last 5 trading sessions, MURA fell by -61.30%, which changed the moving average for the period of 200-days by -50.99% in comparison to the 20-day moving average, which settled at $3.65. In addition, Mural Oncology plc saw -49.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MURA starting from Loew Caroline, who proposed sale 4,313 shares at the price of $3.36 back on Mar 04 ’25. After this action, Loew Caroline now owns shares of Mural Oncology plc, valued at $14,491 using the latest closing price.
Keson-Brookes Maiken, the insider of Mural Oncology plc, sale 1,469 shares at $3.45 during a trade that took place back on Mar 05 ’25, which means that Keson-Brookes Maiken is holding 73,564 shares at $5,068 based on the most recent closing price.
Stock Fundamentals for MURA
The total capital return value is set at -0.97. Equity return is now at value -63.57, with -54.55 for asset returns.
Based on Mural Oncology plc (MURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -16.02.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.83.
Conclusion
To put it simply, Mural Oncology plc (MURA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
